Out of an abundance of precaution, Cipla further said the specified six batches manufactured using the same lot of valves are being recalled.
Drugs Controller General of India (DCGI) granted permission to Mumbai-based pharmaceutical firm Cipla to import Moderna COVID-19 vaccine for India.
Mumbai-based pharmaceutical firm Cipla has received the Drugs Controller General of India (DCGI) nod to import Moderna’s COVID-19 vaccine for restricted emergency use in India, sources told news agency PTI.
Moderna seeks regulatory approval for its COVID-19 vaccine in India. Cipla has also applied for authorisation to import and marketing of Moderna jabs in the country.
ViraGen is Cipla's third offering in the Covid testing segment. Cipla already has partnerships for antibody detection kit and antigen test kits.
This collaboration is a step further in the company's efforts to enhance access to critical treatments for patients affected by the pandemic, Cipla said in a statement.
Drug firm Cipla on Wednesday announced the launch of antibody detection kits for COVID-19 in India under the brand name 'ELIFast' in partnership with KARWA Ltd, under the technology transfer from the Indian Council of Medical Research (ICMR).
Equity benchmark indices shaved off early gains but ended in the positive terrain on Monday with pharma stocks leading the rally.
Drug firm Cipla on Friday reported a 26.58 per cent rise in its consolidated net profit to Rs 566.04 crore for the quarter ended June on the back of robust sales.
Besides scaling up production of medicines that show potency against the virus -- Lopinavir + Ritonavir, Hydroxychloroquine and Azithromycin, the company is also ramping up manufacturing of drugs for chronic ailments such as asthma, COPD, among others, Hamied said.
Equity benchmark indices swung nearly 1 per cent lower during the afternoon session on July 30 ahead of the expiry day of monthly futures and options contracts.
Hyderabad-based Avra Laboratories Pvt Ltd announced on Monday that it had received regulatory approval from the Central Drugs Standard Control Organisation (CDSCO) to manufacture and market Favipiravir Active Pharmaceutical Ingredient (API) for treatment of COVID-19.
Pharmaceutical firm Cipla is set to launch COVID-19 drug Favipiravir, developed by the Council of Scientific and Industrial Research (CSIR) in a cost-effective process. Cipla has scaled up the process in their manufacturing facility and approached DCGI (Drug Controller General of India) for permission to launch the product in India.
The the civil action filed by Cipla in the U.S. District Court for the District of Delaware in January 2019 has been resolved as between Cipla and Amgen Inc, the drug major said on Monday (20 July).
Pharma major Cipla on Wednesday said it has launched its generic version of antiviral drug remdesivir at a price which is among the lowest globally and is looking to supply over 80,000 vials within the first month.
Pharma major Cipla will price its generic version of antiviral drug remdesivir at less than Rs 5,000 per vial in keeping with its conviction of providing access to the medicines at affordable cost, the company said on Tuesday.
With pharmaceutical companies launching generic versions of Remdesivir and Favipiravir for COVID-19 treatment, medical experts on Monday said it was a "positive development" in the fight against the pandemic, but cautioned against regarding the antiviral drugs as "game changers".
Cipla, an Indian multinational pharmaceutical and biotechnology company, has launched its own antiviral drug named Cipremi for treating COVID-19 patients.
Homegrown pharma major Cipla Ltd announced the launch of its generic version of remdesivir, which has been authorised for emergency use in the treatment of COVID-19 patients by the USFDA, under its brand name Cipremi.
Homegrown pharma major Cipla Ltd on Wednesday said it has signed a non-exclusive licensing agreement with Gilead Sciences Inc for manufacturing and distribution of investigational drug remdesivir, a potential therapy for COVID-19.
Top News
Latest News
